cGAMP loading enhances the immunogenicity of VLP vaccines

Cyclic GMP-AMP (cGAMP) is an immunostimulatory second messenger produced by cGAS that activates STING. Soluble cGAMP acts as an adjuvant when administered with antigens. cGAMP is also incorporated into enveloped virus particles during budding. We hypothesised that inclusion of the adjuvant cGAMP within viral vaccine vectors would promote adaptive immunity against vector antigens. We immunised mice with virus-like particles (VLPs) containing the HIV-1 Gag protein and VSV-G. Inclusion of cGAMP within these VLPs augmented splenic VLP-specific CD4 and CD8 T cell responses. It also increased VLP- and VSV-G-specific serum antibody titres and enhanced in vitro virus neutralisation. The superior antibody response was accompanied by increased numbers of T follicular helper cells in draining lymph nodes. Vaccination with cGAMP-loaded VLPs containing haemagglutinin induced high titres of influenza A virus neutralising antibodies and conferred protection following subsequent influenza A virus challenge. Together, these results show that incorporating cGAMP into VLPs enhances their immunogenicity, making cGAMP-VLPs an attractive platform for novel vaccination strategies. Short summary cGAMP is an innate immune signalling molecule that can be transmitted between cells by inclusion in enveloped virions. This study demonstrates enhanced immunogenicity of HIV-derived virus-like particles containing cGAMP. Viral vectors loaded with cGAMP may thus be potent vaccines.

[1]  T. Niewold.  Type I interferon , 2020, Cytokine.

[2]  F. Krammer.  The human antibody response to influenza A virus infection and vaccination , 2019, Nature Reviews Immunology.

[3]  Zhihui Liang,et al.  Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. , 2019, Vaccine.

[4]  S. Crotty.  T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. , 2019, Immunity.

[5]  J. Cyster,et al.  B Cell Responses: Cell Interaction Dynamics and Decisions , 2019, Cell.

[6]  V. Appay,et al.  Priming of HIV-1-specific CD8+ T cells with strong functional properties from naïve T cells , 2019, EBioMedicine.

[7]  E. Graves,et al.  Extracellular 2’3’-cGAMP is an immunotransmitter produced by cancer cells and regulated by ENPP1 , 2019 .

[8]  Fuping Zhang,et al.  B Cells Are the Dominant Antigen‐Presenting Cells that Activate Naive CD4+ T Cells upon Immunization with a Virus‐Derived Nanoparticle Antigen , 2018, Immunity.

[9]  K. Ishii,et al.  Combination and inducible adjuvants targeting nucleic acid sensors , 2018, Current opinion in pharmacology.

[10]  M. Milone,et al.  Clinical use of lentiviral vectors , 2018, Leukemia.

[11]  S. H. van der Burg,et al.  Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections , 2018, Front. Immunol..

[12]  W. Annaert,et al.  Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein , 2017, Journal of Virology.

[13]  Alice Mayer,et al.  Purification of Cyclic GMP-AMP from Viruses and Measurement of Its Activity in Cell Culture , 2017, Methods in molecular biology.

[14]  Zhijian J. Chen,et al.  cGAS is essential for the antitumor effect of immune checkpoint blockade , 2017, Proceedings of the National Academy of Sciences.

[15]  Andrea J. Radtke,et al.  Water-in-Oil–Only Adjuvants Selectively Promote T Follicular Helper Cell Polarization through a Type I IFN and IL-6–Dependent Pathway , 2016, The Journal of Immunology.

[16]  J. Blattman,et al.  Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination. , 2016, Vaccine.

[17]  Mei X. Wu,et al.  Natural STING Agonist as an "Ideal" Adjuvant for Cutaneous Vaccination. , 2016, The Journal of investigative dermatology.

[18]  M. Nielsen,et al.  NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets , 2016, Genome Medicine.

[19]  M. Linterman,et al.  Can follicular helper T cells be targeted to improve vaccine efficacy? , 2016, F1000Research.

[20]  Xiangshi Tan,et al.  Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response , 2016, Scientific Reports.

[21]  F. Martinon,et al.  STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity , 2015, Proceedings of the National Academy of Sciences.

[22]  M. Piechaczyk,et al.  Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents? , 2015, Trends in Microbiology.

[23]  G. Kroemer,et al.  Transmission of innate immune signaling by packaging of cGAMP in viral particles , 2015, Science.

[24]  P. Borrow,et al.  Viruses transfer the antiviral second messenger cGAMP between cells , 2015, Science.

[25]  George E. Katibah,et al.  Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.

[26]  Lei Jin,et al.  The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates pinocytosis-efficient cells in vivo , 2015, eLife.

[27]  T. Mitchison,et al.  Hydrolysis of 2′3′-cGAMP by ENPP1 and design of non-hydrolyzable analogs , 2014, Nature chemical biology.

[28]  Zhijian J. Chen,et al.  The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. , 2014, Molecular cell.

[29]  Lei Jin,et al.  MPYS/STING-Mediated TNF-α, Not Type I IFN, Is Essential for the Mucosal Adjuvant Activity of (3′–5′)-Cyclic-Di-Guanosine-Monophosphate In Vivo , 2014, The Journal of Immunology.

[30]  Zhijian J. Chen,et al.  Pivotal Roles of cGAS-cGAMP Signaling in Antiviral Defense and Immune Adjuvant Effects , 2013, Science.

[31]  D. Kanne,et al.  Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants , 2013, Therapeutic advances in vaccines.

[32]  V. Hornung,et al.  cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING , 2013, Nature.

[33]  R. Vance,et al.  The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. , 2013, Cell reports.

[34]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway , 2013, Science.

[35]  Loise M. Francisco,et al.  The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood , 2012, Nature Immunology.

[36]  E. Fodor,et al.  Pseudotyped Influenza A Virus as a Vaccine for the Induction of Heterotypic Immunity , 2012, Journal of Virology.

[37]  C. Mandl,et al.  Vaccines for the twenty-first century society , 2011, Nature Reviews Immunology.

[38]  Yoshihiro Hayakawa,et al.  STING is a direct innate immune sensor of cyclic-di-GMP , 2011, Nature.

[39]  T. Ebensen,et al.  Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. , 2011, Vaccine.

[40]  Matthew S. Lewis,et al.  Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.

[41]  R. Coffman,et al.  Vaccine adjuvants: putting innate immunity to work. , 2010, Immunity.

[42]  U. Yrlid,et al.  Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. , 2009, Immunity.

[43]  R. Nurieva,et al.  Bcl6 Mediates the Development of T Follicular Helper Cells , 2009, Science.

[44]  M. Nolte,et al.  Inflammatory signals in dendritic cell activation and the induction of adaptive immunity , 2009, Immunological reviews.

[45]  D. Baltimore,et al.  Engineered lentivector targeting of dendritic cells for in vivo immunization , 2008, Nature Biotechnology.

[46]  R. Steinman,et al.  Intensified and protective CD4+ T cell immunity in mice with anti–dendritic cell HIV gag fusion antibody vaccine , 2006, The Journal of experimental medicine.

[47]  R. Wagner,et al.  Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. , 2005, Molecular immunology.

[48]  Aaron J. Johnson,et al.  Cellular and Humoral Immunity against Vaccinia Virus Infection of Mice 1 , 2004, The Journal of Immunology.

[49]  R. Siliciano,et al.  Novel Single-Cell-Level Phenotypic Assay for Residual Drug Susceptibility and Reduced Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1 , 2004, Journal of Virology.

[50]  M. Jenkins,et al.  Antigen presentation to naive CD4 T cells in the lymph node , 2003, Nature Immunology.

[51]  William C Hahn,et al.  Lentivirus-delivered stable gene silencing by RNAi in primary cells. , 2003, RNA.

[52]  A. O’Garra,et al.  Cytokines induce the development of functionally heterogeneous T helper cell subsets. , 1998, Immunity.

[53]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[54]  G. Pavlakis,et al.  Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression , 1992, Journal of virology.

[55]  K. Nagashima,et al.  Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[56]  D. Brahams.  Human immunodeficiency virus and the law. , 1987, Lancet.

[57]  S. Fields,et al.  Nucleotide sequence of the haemagglutinin gene of a human influenza virus H1 subtype , 1981, Nature.

[58]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .